Zacks Research Issues Pessimistic Outlook for CPRX Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Research analysts at Zacks Research lowered their Q4 2024 earnings estimates for shares of Catalyst Pharmaceuticals in a report released on Wednesday, November 27th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.46 per share for the quarter, down from their prior estimate of $0.48. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.57 EPS, Q2 2026 earnings at $0.58 EPS and FY2026 earnings at $2.36 EPS.

Other equities analysts have also recently issued research reports about the stock. Citigroup upped their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Stephens began coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Truist Financial upped their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Trading Down 3.6 %

Shares of Catalyst Pharmaceuticals stock opened at $21.71 on Monday. The company’s fifty day simple moving average is $21.32 and its two-hundred day simple moving average is $18.87. The company has a market cap of $2.59 billion, a P/E ratio of 18.40, a PEG ratio of 3.44 and a beta of 0.75. Catalyst Pharmaceuticals has a 12-month low of $13.00 and a 12-month high of $24.27.

Insider Activity

In related news, Director Molly Harper sold 17,500 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Pacer Advisors Inc. boosted its position in Catalyst Pharmaceuticals by 130,918.8% in the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after buying an additional 2,965,310 shares during the last quarter. Renaissance Technologies LLC boosted its position in Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after buying an additional 287,300 shares during the last quarter. Jane Street Group LLC boosted its position in Catalyst Pharmaceuticals by 245.4% in the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock valued at $7,990,000 after buying an additional 285,564 shares during the last quarter. Integral Health Asset Management LLC purchased a new stake in Catalyst Pharmaceuticals in the second quarter valued at approximately $4,260,000. Finally, Dimensional Fund Advisors LP boosted its position in Catalyst Pharmaceuticals by 9.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after purchasing an additional 263,099 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.